Coloplast A/S (OTCMKTS:CLPBY – Get Rating) has been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $1,038.00.
Separately, JPMorgan Chase & Co. cut their price objective on shares of Coloplast A/S from 1,014.00 to 980.00 and set a “neutral” rating for the company in a research report on Tuesday, May 10th.
Coloplast A/S stock opened at $11.68 on Tuesday. Coloplast A/S has a 12-month low of $11.32 and a 12-month high of $18.90. The stock has a market cap of $25.23 billion, a P/E ratio of 38.93 and a beta of 0.28. The company has a 50-day moving average price of $13.57 and a 200 day moving average price of $14.75. The company has a current ratio of 1.29, a quick ratio of 0.90 and a debt-to-equity ratio of 0.02.
Coloplast A/S Company Profile (Get Rating)
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
- Get a free copy of the StockNews.com research report on Coloplast A/S (CLPBY)
- Target’s Warning Is Dire News For The S&P 500
- The Key Number That Explains Why CrowdStrike May Power Higher
- DoubleVerify Holding Stock attempts a Double Bottom
- Teladoc Health Stock is Pricing Right
- Two Consumer Staples With Bright Outlook For Dark Times
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.